Download PDF
Zeitschrift für Phytotherapie 2024; 45(04): 148-156
DOI: 10.1055/a-2171-9349
Forschung

Die Rolle von Phytotherapie bei COVID-19-assoziierter Angst und Depression

Beispiele aus der PraxisThe Role of Phytotherapy in the Treatment of Anxiety and Depression Occurring in the Context of COVID-19: Clinical Case Reports
Jan Zourek
1   Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien, Wien, Österreich
,
Rainer Stange
2   Charité – Universitätsmedizin Berlin und Immanuel Krankenhaus, Abteilung für Naturheilkunde, Berlin, Deutschland
,
Siegfried Kasper
1   Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien, Wien, Österreich
3   Zentrum für Hirnforschung, Medizinische Universität Wien, Wien, Österreich
,
Lucie Bartova
1   Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien, Wien, Österreich
› Author Affiliations Finanzielle Unterstützung Der vorliegende Artikel wurde ohne finanzielle Unterstützung von öffentlichen, kommerziellen oder gemeinnützigen Einrichtungen verfasst.
› Further Information
    Permissions and Reprints

Zusammenfassung

Der vorliegende Artikel bietet einen Überblick über die Anwendung von Phytotherapie bei psychiatrischen Manifestationen, die im Kontext von COVID-19 aufgetreten sind. Insbesondere wird der Einsatz des mit eigenen Anteilen angereicherten Lavendelöls Silexan® (aus Lavandula angustifolia Mill.), des aus Ginkgo (Ginkgo biloba L.) hergestellten Extraktes EGb 761® sowie des Extraktes SHR-5 aus Rosenwurz (Rhodiola rosea L.) beleuchtet, die bereits Erfolge in der Behandlung von vordergründig milden Angstzuständen, depressiven, psychosomatischen und kognitiven Symptomen zeigten. Diese zählen zu den am häufigsten auftretenden Beschwerden im Rahmen des sog. Long-COVID-Syndroms.

Im Detail stellen wir 4 Fälle vor, die unsere ersten klinischen Erfahrungen mit Silexan® bei erwachsenen ambulanten Patienten mit sowohl subsyndromalen als auch voll ausgeprägten Angsterkrankungen und depressiven Zustandsbildern illustrieren, die in Zusammenhang mit COVID-19 aufgetreten sind. In Anbetracht der langfristigen negativen Auswirkungen auf die Gesundheit, Lebensqualität und Funktionalität der Betroffenen, denen durch eine frühe diagnostische Zuordnung und eine rechtzeitige adäquate Behandlung vorgebeugt werden kann, scheint ein evidenzbasierter Einsatz von Phytotherapie in der Behandlung von COVID-19-assoziierten psychiatrischen Manifestationen, die vor allem subsyndromale Ausprägung aufweisen, eine wichtige und klinisch sehr relevante Rolle zu spielen.

Abstract

This article provides an overview of the evidence-based administration of phytotherapy for psychiatric manifestations that have occurred in the context of COVID-19. In particular, we focus on a modified lavender oil enriched by its own components Silexan® (Lavandula angustifolia Mill.), the extract EGb 761® derived from ginkgo (Ginkgo biloba L.) as well as the extract SHR-5 from rose root (Rhodiola rosea L.), which have already shown success in the treatment of anxiety, depressive, psychosomatic, and cognitive symptoms, especially of the so-called subthreshold or subsyndromal extent. Importantly, subsyndromal manifestations of these psychiatric conditions rank among the most frequently occurring complaints in the context of the so-called Long COVID syndrome.

Here, we present four cases that illustrate our initial clinical experience with Silexan® in adult outpatients with both subsyndromal and full-blown anxiety and depression with accompanying psychosomatic and cognitive symptoms that have occurred in the context of COVID-19. Considering the long-term negative effects on the health, quality of life and functionality of patients affected by these symptoms, which can be prevented by early diagnosis and timely and adequate treatment, the evidence-based use of phytotherapy appears to play an important and clinically relevant role in the treatment of COVID-19-associated psychiatric manifestations, which are mainly subsyndromal in nature.

Keywords

COVID-19 - anxiety - depression - subsyndromal - phytotherapy - Silexan®

Schlüsselwörter

COVID-19 - Angst - Depression - subsyndromal - Phytotherapie - Silexan®


Publication History

Article published online:
13 August 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz (BMSGPK). ICD-10. BMSGPK 2024 – Systematisches Verzeichnis. 2024
    PubMed
  • 2 Jacobson KB, Rao M, Bonilla H. et al. Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clin Infect Dis 2021; 73: e826-e829
    CrossrefPubMedSearch in Google Scholar
  • 3 Peter RS, Nieters A, Kräusslich HG. et al. EPILOC Phase 1 Study Group. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ 2022; 379: e071050
    CrossrefPubMedSearch in Google Scholar
  • 4 Zürcher SJ, Banzer C, Adamus C. et al. Post-viral mental health sequelae in infected persons associated with COVID-19 and previous epidemics and pandemics: Systematic review and meta-analysis of prevalence estimates. J Infect Public Health 2022; 15: 599-608
    CrossrefPubMedSearch in Google Scholar
  • 5 Volz HP, Saliger J, Kasper S. et al. Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey. Int J Psychiatry Clin Pract 2022; 26: 277-286
    CrossrefPubMedSearch in Google Scholar
  • 6 Volz HP, Stirnweiß J, Kasper S. et al. Subthreshold depression – concept, operationalisation and epidemiological data. A scoping review. Int J Psychiatry Clin Pract 2023; 27: 92-106
    CrossrefPubMedSearch in Google Scholar
  • 7 Ida FS, Ferreira HP, Vasconcelos AKM. et al. Post-COVID-19 syndrome: persistent symptoms, functional impact, quality of life, return to work, and indirect costs – a prospective case study 12 months after COVID-19 infection. Cad Saúde Pública 2024; 40: e00022623
    CrossrefPubMedSearch in Google Scholar
  • 8 Malesevic S, Sievi NA, Baumgartner P. et al. Impaired health-related quality of life in long-COVID syndrome after mild to moderate COVID-19. Sci Rep 2023; 13: 7717
    CrossrefPubMedSearch in Google Scholar
  • 9 Bartova L, Dold M, Volz HP. et al. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. Eur Arch Psychiatry Clin Neurosci 2022; 273: 51-63
    CrossrefPubMedSearch in Google Scholar
  • 10 Sarris J, Ravindran A, Yatham LN. et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry 2022; 23: 424-455
    CrossrefPubMedSearch in Google Scholar
  • 11 Bartova L, Dold M, Fugger G. et al. Silexan for treatment of anxiety and depression in the context of COVID-19. Eur Neuropsychopharmacol 2023; 70: 47-48
    CrossrefPubMedSearch in Google Scholar
  • 12 Kasper S, Volz HP, Möller HJ. et al. Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial. Eur Arch Psychiatry Clin Neurosci 2024; [Online ahead of print]
    CrossrefPubMedSearch in Google Scholar
  • 13 Dold M, Bartova L, Volz HP. et al. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 2023; 273: 1615-1628
    CrossrefPubMedSearch in Google Scholar
  • 14 Mueller JK, Müller WE. Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea . J Neural Transm 2024; 131: 203-212
    CrossrefPubMedSearch in Google Scholar
  • 15 Kasper S, Eckert A, Möller HJ. et al. Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan. Int J Psychiatry Clin Pract 2023; 27: 285-291
    CrossrefPubMedSearch in Google Scholar
  • 16 Ihl R, Frölich L, Winblad B. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry 2011; 12: 2-32
    CrossrefPubMedSearch in Google Scholar
  • 17 Grass-Kapanke B, Busmane A, Lasmanis A. et al. Effects of Ginkgo biloba special extract EGb 761® in very mild cognitive impairment (vMCI). Neurosci Med 2011; 2: 48-56
    CrossrefPubMedSearch in Google Scholar
  • 18 Gschwind YJ, Bridenbaugh SA, Reinhard S. et al. Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study. Aging Clin Exp Res 2017; 29: 609-619
    CrossrefPubMedSearch in Google Scholar
  • 19 Zifko U, Guendling K, Seet R. et al. Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care. Front Pharmacol 2024; 15: 1338235
    CrossrefPubMedSearch in Google Scholar
  • 20 Liu X, Hao W, Qin Y. et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer’s disease. Brain Behav Immun 2015; 46: 121-131
    CrossrefPubMedSearch in Google Scholar
  • 21 Kasper S, Bancher C, Eckert A. et al. Management of mild cognitive impairment (MCI): The need for national and international guidelines. World J Biol Psychiatry 2020; 21: 579-594
    CrossrefPubMedSearch in Google Scholar
  • 22 Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Ginkgo biloba L., folium. EMA/HMPC/321097/2012
    PubMed
  • 23 Anghelescu IG, Edwards D, Seifritz E. et al. Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract 2018; 22: 242-252
    CrossrefPubMedSearch in Google Scholar
  • 24 Lee Y, Jung J-C, Jang S. et al. Anti-inflammatory and neuroprotective effects of constituents isolated from Rhodiola rosea . Evid Based Complement Alternat Med 2013; 2013: 514049
    CrossrefPubMedSearch in Google Scholar
  • 25 Dold M, Möller HJ, Volz HP. et al. Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials. Eur Psychiatry 2024; 67: e23
    CrossrefPubMedSearch in Google Scholar
  • 26 Baldinger P, Höflich AS, Mitterhauser M. et al. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol 2014; 18: pyu063
    CrossrefPubMedSearch in Google Scholar
  • 27 Baldinger-Mehlich P, Spies M, Lanzeberger R, Kasper S. Der Stellenwert der Phytomedizin in der Psychiatrie. CliniCum neuropsy. 01/2018. https://oegpb.at/2018/04/04/der-stellenwert-der-phytomedizin-in-der-psychiatrie
    PubMed
  • 28 Friedland K, Silani G, Schuwald A. et al. Neurotrophic properties of Silexan, an essential oil from the flowers of lavender--preclinical evidence for antidepressant-like properties. Pharmacopsychiatry 2021; 54: 37-46
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Müller WE, Sillani G, Schuwald A. et al. Pharmacological basis of the anxiolytic and antidepressant properties of Silexan®, an essential oil from the flowers of lavender. Neurochem Int 2021; 143: 104899
    CrossrefPubMedSearch in Google Scholar
  • 30 Möller HJ, Volz HP, Dienel A. et al. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 2019; 269: 183-193
    CrossrefPubMedSearch in Google Scholar
  • 31 von Känel R, Kasper S, Bondolfi G. et al. Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. Brain Behav 2021; 11: e01997
    CrossrefPubMedSearch in Google Scholar
  • 32 Kasper S, Möller HJ, Volz HP. et al. Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. Int Clin Psychopharmacol 2017; 32: 195-204
    CrossrefPubMedSearch in Google Scholar
  • 33 Kasper S, Volz HP, Dienel A. et al. Efficacy of Silexan in mixed anxiety-depression – A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2016; 26: 331-340
    CrossrefPubMedSearch in Google Scholar
  • 34 Kasper S, Anghelescu I, Dienel A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015; 25: 1960-1967
    CrossrefPubMedSearch in Google Scholar
  • 35 Kasper S. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. Int J Psychiatry Clin Pract 2013; 17: 15-22
    CrossrefPubMedSearch in Google Scholar
  • 36 Seifritz E, Schläfke S, Holsboer-Trachsler E. Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect. J Psychiatr Res 2019; 115: 69-74
    CrossrefPubMedSearch in Google Scholar
  • 37 Kasper S, Gastpar M, Müller WE. et al. Efficacy and safety of Silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials. Wien Med Wochenschr 2010; 160: 547-556
    CrossrefPubMedSearch in Google Scholar
  • 38 Yap WS, Dolzhenko AV, Jalal Z. et al. Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis. Sci Rep 2019; 9: 18042
    CrossrefPubMedSearch in Google Scholar
  • 39 Lavendelöl. [Pflanzliche Stoffe und Zubereitungen: Zusammenfassung für die Öffentlichkeit]. EMA/HMPC/530968/2012.
    PubMed
  • 40 COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; 398: 1700-1712
    CrossrefPubMedSearch in Google Scholar
  • 41 Zifko UA, Yacob M, Braun BJ. et al. Alleviation of post-COVID-19 cognitive deficits by treatment with EGb 761®: A case series. Am J Case Rep 2022; 23: e937094
    CrossrefPubMedSearch in Google Scholar
  • 42 Taquet M, Dercon Q, Luciano S. et al. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021; 18: e1003773
    CrossrefPubMedSearch in Google Scholar
  • 43 Doykov I, Hällqvist J, Gilmour KC. et al. ’The long tail of Covid-19’ - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res 2020; 9: 1349
    CrossrefPubMedSearch in Google Scholar
  • 44 Kasper S, Gastpar M, Müller WE. et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 2010; 25: 277-287
    CrossrefPubMedSearch in Google Scholar
  • 45 Kasper S, Gastpar M, Müller WE. et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 2014; 17: 859-869
    CrossrefPubMedSearch in Google Scholar
  • 46 Möller H-J, Volz H-P, Seifritz E. et al. Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. J Psychiatr Res 2021; 136: 543-551
    CrossrefPubMedSearch in Google Scholar
  • 47 Seifritz E, Möller HJ, Volz HP. et al. No abuse potential of Silexan in healthy recreational drug users: A randomized controlled trial. Int J Neuropsychopharmacol 2021; 24: 171-180
    CrossrefPubMedSearch in Google Scholar
  • 48 Bartova L, Fugger G, Dold M. et al. Therapieoptionen bei Angsterkrankungen unter Berücksichtigung der Phyto-Psychopharmakotherapie // Treatment Strategies of Anxiety Disorders: The Role of Phyto-Psychopharmacotherapy. Journal für Neurologie. Neurochirurgie und Psychiatrie 2022; 23: 124-130
    PubMedSearch in Google Scholar
  • 49 Fenton C, Lee A. Antidepressants with anti-inflammatory properties may be useful in long COVID depression. Drugs Ther Perspect 2023; 39: 65-70
    CrossrefPubMedSearch in Google Scholar
  • 50 Victor MM, Müller Haas L, Grevet EH. et al. Successful treatment of post-COVID-19 ADHD-like syndrome: A case report. J Atten Disord 2023; 27: 1092-1098
    CrossrefPubMedSearch in Google Scholar
  • 51 Mahdi M, Hermán L, Réthelyi JM. et al. Potential role of the antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19. Int J Mol Sci 2022; 23: 3812
    CrossrefPubMedSearch in Google Scholar
  • 52 Reinfeld S. Can bupropion treat COVID-19-induced brain fog? A case series. Int Clin Psychopharmacol 2023; 38: 189-191
    CrossrefPubMedSearch in Google Scholar